Tenofovir Alafenamide for Pregnant Chinese Women With Active Chronic Hepatitis B: A Multicenter Prospective Study
Data on long-term tenofovir alafenamide (TAF) therapy for pregnant women with active chronic hepatitis B (CHB) (immune clearance and reactivation phases, currently and previously diagnosed) and their infants are lacking. Pregnant women with active CHB treated with TAF and tenofovir disoproxil fumara...
Saved in:
| Published in | Clinical gastroenterology and hepatology Vol. 20; no. 12; pp. 2826 - 2837.e9 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
01.12.2022
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Data on long-term tenofovir alafenamide (TAF) therapy for pregnant women with active chronic hepatitis B (CHB) (immune clearance and reactivation phases, currently and previously diagnosed) and their infants are lacking.
Pregnant women with active CHB treated with TAF and tenofovir disoproxil fumarate (TDF) were enrolled in this multicenter prospective study, and infants received immunoprophylaxis. The primary outcomes were rates of adverse (safety) events in pregnant women and defects in infants and fetuses. The secondary outcomes were virologic responses in pregnant women, infants’ safety, hepatitis B surface antigen (HBsAg) status, and growth conditions.
One hundred three and 104 pregnant women were enrolled and 102 and 104 infants were born in the TAF and TDF groups, respectively. In the TAF group, the mean age, gestational age, alanine aminotransferase level, and viral loads at treatment initiation were 29.3 years, 1.3 weeks, 122.2 U/L, and 5.1 log10 IU/mL, respectively. TAF was well-tolerated, and the most common adverse event was nausea (29.1%) during a mean of 2 years of treatment. Notably, 1 (1.0%) TAF-treated pregnant woman underwent induced abortion due to noncausal fetal cleft lip and palate. No infants in either group had birth defects. In the TAF group, the hepatitis B e antigen seroconversion rate was 20.7% at postpartum month 6, infants had normal growth parameters, and no infants were positive for HBsAg at 7 months. The TDF group had comparable safety and effectiveness profiles.
TAF administered throughout or beginning in early pregnancy is generally safe and effective for pregnant women with active CHB and their infants.
[Display omitted] |
|---|---|
| AbstractList | Data on long-term tenofovir alafenamide (TAF) therapy for pregnant women with active chronic hepatitis B (CHB) (immune clearance and reactivation phases, currently and previously diagnosed) and their infants are lacking.BACKGROUND & AIMSData on long-term tenofovir alafenamide (TAF) therapy for pregnant women with active chronic hepatitis B (CHB) (immune clearance and reactivation phases, currently and previously diagnosed) and their infants are lacking.Pregnant women with active CHB treated with TAF and tenofovir disoproxil fumarate (TDF) were enrolled in this multicenter prospective study, and infants received immunoprophylaxis. The primary outcomes were rates of adverse (safety) events in pregnant women and defects in infants and fetuses. The secondary outcomes were virologic responses in pregnant women, infants' safety, hepatitis B surface antigen (HBsAg) status, and growth conditions.METHODSPregnant women with active CHB treated with TAF and tenofovir disoproxil fumarate (TDF) were enrolled in this multicenter prospective study, and infants received immunoprophylaxis. The primary outcomes were rates of adverse (safety) events in pregnant women and defects in infants and fetuses. The secondary outcomes were virologic responses in pregnant women, infants' safety, hepatitis B surface antigen (HBsAg) status, and growth conditions.One hundred three and 104 pregnant women were enrolled and 102 and 104 infants were born in the TAF and TDF groups, respectively. In the TAF group, the mean age, gestational age, alanine aminotransferase level, and viral loads at treatment initiation were 29.3 years, 1.3 weeks, 122.2 U/L, and 5.1 log10 IU/mL, respectively. TAF was well-tolerated, and the most common adverse event was nausea (29.1%) during a mean of 2 years of treatment. Notably, 1 (1.0%) TAF-treated pregnant woman underwent induced abortion due to noncausal fetal cleft lip and palate. No infants in either group had birth defects. In the TAF group, the hepatitis B e antigen seroconversion rate was 20.7% at postpartum month 6, infants had normal growth parameters, and no infants were positive for HBsAg at 7 months. The TDF group had comparable safety and effectiveness profiles.RESULTSOne hundred three and 104 pregnant women were enrolled and 102 and 104 infants were born in the TAF and TDF groups, respectively. In the TAF group, the mean age, gestational age, alanine aminotransferase level, and viral loads at treatment initiation were 29.3 years, 1.3 weeks, 122.2 U/L, and 5.1 log10 IU/mL, respectively. TAF was well-tolerated, and the most common adverse event was nausea (29.1%) during a mean of 2 years of treatment. Notably, 1 (1.0%) TAF-treated pregnant woman underwent induced abortion due to noncausal fetal cleft lip and palate. No infants in either group had birth defects. In the TAF group, the hepatitis B e antigen seroconversion rate was 20.7% at postpartum month 6, infants had normal growth parameters, and no infants were positive for HBsAg at 7 months. The TDF group had comparable safety and effectiveness profiles.TAF administered throughout or beginning in early pregnancy is generally safe and effective for pregnant women with active CHB and their infants.CONCLUSIONSTAF administered throughout or beginning in early pregnancy is generally safe and effective for pregnant women with active CHB and their infants. Data on long-term tenofovir alafenamide (TAF) therapy for pregnant women with active chronic hepatitis B (CHB) (immune clearance and reactivation phases, currently and previously diagnosed) and their infants are lacking. Pregnant women with active CHB treated with TAF and tenofovir disoproxil fumarate (TDF) were enrolled in this multicenter prospective study, and infants received immunoprophylaxis. The primary outcomes were rates of adverse (safety) events in pregnant women and defects in infants and fetuses. The secondary outcomes were virologic responses in pregnant women, infants’ safety, hepatitis B surface antigen (HBsAg) status, and growth conditions. One hundred three and 104 pregnant women were enrolled and 102 and 104 infants were born in the TAF and TDF groups, respectively. In the TAF group, the mean age, gestational age, alanine aminotransferase level, and viral loads at treatment initiation were 29.3 years, 1.3 weeks, 122.2 U/L, and 5.1 log10 IU/mL, respectively. TAF was well-tolerated, and the most common adverse event was nausea (29.1%) during a mean of 2 years of treatment. Notably, 1 (1.0%) TAF-treated pregnant woman underwent induced abortion due to noncausal fetal cleft lip and palate. No infants in either group had birth defects. In the TAF group, the hepatitis B e antigen seroconversion rate was 20.7% at postpartum month 6, infants had normal growth parameters, and no infants were positive for HBsAg at 7 months. The TDF group had comparable safety and effectiveness profiles. TAF administered throughout or beginning in early pregnancy is generally safe and effective for pregnant women with active CHB and their infants. [Display omitted] Background & AimsData on long-term tenofovir alafenamide (TAF) therapy for pregnant women with active chronic hepatitis B (CHB) (immune clearance and reactivation phases, currently and previously diagnosed) and their infants are lacking. MethodsPregnant women with active CHB treated with TAF and tenofovir disoproxil fumarate (TDF) were enrolled in this multicenter prospective study, and infants received immunoprophylaxis. The primary outcomes were rates of adverse (safety) events in pregnant women and defects in infants and fetuses. The secondary outcomes were virologic responses in pregnant women, infants’ safety, hepatitis B surface antigen (HBsAg) status, and growth conditions. ResultsOne hundred three and 104 pregnant women were enrolled and 102 and 104 infants were born in the TAF and TDF groups, respectively. In the TAF group, the mean age, gestational age, alanine aminotransferase level, and viral loads at treatment initiation were 29.3 years, 1.3 weeks, 122.2 U/L, and 5.1 log 10 IU/mL, respectively. TAF was well-tolerated, and the most common adverse event was nausea (29.1%) during a mean of 2 years of treatment. Notably, 1 (1.0%) TAF-treated pregnant woman underwent induced abortion due to noncausal fetal cleft lip and palate. No infants in either group had birth defects. In the TAF group, the hepatitis B e antigen seroconversion rate was 20.7% at postpartum month 6, infants had normal growth parameters, and no infants were positive for HBsAg at 7 months. The TDF group had comparable safety and effectiveness profiles. ConclusionsTAF administered throughout or beginning in early pregnancy is generally safe and effective for pregnant women with active CHB and their infants. Data on long-term tenofovir alafenamide (TAF) therapy for pregnant women with active chronic hepatitis B (CHB) (immune clearance and reactivation phases, currently and previously diagnosed) and their infants are lacking. Pregnant women with active CHB treated with TAF and tenofovir disoproxil fumarate (TDF) were enrolled in this multicenter prospective study, and infants received immunoprophylaxis. The primary outcomes were rates of adverse (safety) events in pregnant women and defects in infants and fetuses. The secondary outcomes were virologic responses in pregnant women, infants' safety, hepatitis B surface antigen (HBsAg) status, and growth conditions. One hundred three and 104 pregnant women were enrolled and 102 and 104 infants were born in the TAF and TDF groups, respectively. In the TAF group, the mean age, gestational age, alanine aminotransferase level, and viral loads at treatment initiation were 29.3 years, 1.3 weeks, 122.2 U/L, and 5.1 log IU/mL, respectively. TAF was well-tolerated, and the most common adverse event was nausea (29.1%) during a mean of 2 years of treatment. Notably, 1 (1.0%) TAF-treated pregnant woman underwent induced abortion due to noncausal fetal cleft lip and palate. No infants in either group had birth defects. In the TAF group, the hepatitis B e antigen seroconversion rate was 20.7% at postpartum month 6, infants had normal growth parameters, and no infants were positive for HBsAg at 7 months. The TDF group had comparable safety and effectiveness profiles. TAF administered throughout or beginning in early pregnancy is generally safe and effective for pregnant women with active CHB and their infants. |
| Author | Xu, Jiang-Hai Li, Guo-Tao Liu, Yan-Min Pan, Ya-Jie Li, Wei Lin, Wan-Bao Wang, Meng Zhang, Ji-Yuan Zhang, Hong-Xu Zeng, Yan-Li Zhang, Guo-Qiang Zeng, Qing-Lei Cui, Guang-Lin Li, Guang-Ming Li, Zhi-Qin Zhang, Da-Wei Song, Ning Wang, Fu-Sheng Huang, Shuo Li, Juan Xu, Guang-Hua Sun, Chang-Yu Zhou, Yi-Hua Liang, Hong-Xia Chen, Zhi-Min Liu, Na Lv, Jun Li, Wei-Zhe Feng, Ying-Hua Zhang, Guo-Fan Yu, Zu-Jiang |
| Author_xml | – sequence: 1 givenname: Qing-Lei orcidid: 0000-0002-2094-4784 surname: Zeng fullname: Zeng, Qing-Lei email: zengqinglei2009@163.com organization: Department of Infectious Diseases and Hepatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province – sequence: 2 givenname: Hong-Xu surname: Zhang fullname: Zhang, Hong-Xu organization: Department of Infectious Diseases, Luohe Central Hospital, Luohe, Henan Province – sequence: 3 givenname: Ji-Yuan surname: Zhang fullname: Zhang, Ji-Yuan organization: Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing – sequence: 4 givenname: Shuo surname: Huang fullname: Huang, Shuo organization: Department of Infectious Diseases and Hepatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province – sequence: 5 givenname: Wei-Zhe surname: Li fullname: Li, Wei-Zhe organization: Department of Infectious Diseases and Hepatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province – sequence: 6 givenname: Guang-Ming surname: Li fullname: Li, Guang-Ming organization: Department of Hepatology, The Sixth People’s Hospital of Zhengzhou City, Zhengzhou, Henan Province – sequence: 7 givenname: Ya-Jie surname: Pan fullname: Pan, Ya-Jie organization: Department of Infectious Diseases and Hepatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province – sequence: 8 givenname: Ying-Hua surname: Feng fullname: Feng, Ying-Hua organization: Department of Hepatology, The Sixth People’s Hospital of Kaifeng City, Kaifeng, Henan Province – sequence: 9 givenname: Zhi-Qin surname: Li fullname: Li, Zhi-Qin organization: Department of Infectious Diseases and Hepatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province – sequence: 10 givenname: Guo-Fan surname: Zhang fullname: Zhang, Guo-Fan organization: Department of Infectious Diseases, The First Affiliated Hospital of Nanyang Medical College, Nanyang, Henan Province – sequence: 11 givenname: Jiang-Hai surname: Xu fullname: Xu, Jiang-Hai organization: Department of Hepatology, The Fifth People’s Hospital of Anyang City, Anyang, Henan Province – sequence: 12 givenname: Wan-Bao surname: Lin fullname: Lin, Wan-Bao organization: Department of Infectious Diseases, Xinyang Central Hospital, Xinyang, Henan Province – sequence: 13 givenname: Guang-Hua surname: Xu fullname: Xu, Guang-Hua organization: Department of Infectious Diseases, The Affiliated Hospital of Yan’an University, Yan’an, Shaanxi Province – sequence: 14 givenname: Na surname: Liu fullname: Liu, Na organization: Department of Infectious Diseases, The Affiliated Hospital of Yan’an University, Yan’an, Shaanxi Province – sequence: 15 givenname: Guo-Qiang surname: Zhang fullname: Zhang, Guo-Qiang organization: Department of Infectious Diseases, Luoyang Central Hospital, Luoyang, Henan Province – sequence: 16 givenname: Guo-Tao surname: Li fullname: Li, Guo-Tao organization: Department of Infectious Diseases, Luoyang Central Hospital, Luoyang, Henan Province – sequence: 17 givenname: Wei surname: Li fullname: Li, Wei organization: Department of Infectious Diseases, Henan Provincial People’s Hospital, Zhengzhou, Henan Province – sequence: 18 givenname: Yan-Li surname: Zeng fullname: Zeng, Yan-Li organization: Department of Infectious Diseases, Henan Provincial People’s Hospital, Zhengzhou, Henan Province – sequence: 19 givenname: Ning surname: Song fullname: Song, Ning organization: Center for Reproductive Medicine, Henan Key Laboratory of Reproduction and Genetics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province – sequence: 20 givenname: Meng surname: Wang fullname: Wang, Meng organization: Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province – sequence: 21 givenname: Da-Wei surname: Zhang fullname: Zhang, Da-Wei organization: Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing – sequence: 22 givenname: Zhi-Min surname: Chen fullname: Chen, Zhi-Min organization: Department of Obstetrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province – sequence: 23 givenname: Guang-Lin surname: Cui fullname: Cui, Guang-Lin organization: Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province – sequence: 24 givenname: Juan surname: Li fullname: Li, Juan organization: Department of Infectious Diseases and Hepatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province – sequence: 25 givenname: Jun surname: Lv fullname: Lv, Jun organization: Department of Infectious Diseases and Hepatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province – sequence: 26 givenname: Yan-Min surname: Liu fullname: Liu, Yan-Min organization: Department of Infectious Diseases and Hepatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province – sequence: 27 givenname: Hong-Xia surname: Liang fullname: Liang, Hong-Xia organization: Department of Infectious Diseases and Hepatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province – sequence: 28 givenname: Chang-Yu surname: Sun fullname: Sun, Chang-Yu organization: Department of Infectious Diseases and Hepatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province – sequence: 29 givenname: Yi-Hua surname: Zhou fullname: Zhou, Yi-Hua organization: Department of Experimental Medicine and Jiangsu Key Laboratory for Molecular Medicine, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu Province, China – sequence: 30 givenname: Zu-Jiang surname: Yu fullname: Yu, Zu-Jiang email: johnyuem@zzu.edu.cn organization: Department of Infectious Diseases and Hepatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province – sequence: 31 givenname: Fu-Sheng surname: Wang fullname: Wang, Fu-Sheng email: fswang302@163.com organization: Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34902570$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkl1rFDEYhYNU7If-AG8kl97smI9JMqMgbBe1QkWhlV6GbOadbtbZZJtkFvbfm2FXLwrWqwRynhPec95zdOKDB4ReU1JRQuW7dWXvVxUjjFaUVYSyZ-iMiprNlKL1yfHOhRSn6DylNSGsrVv1Ap3yuiVMKHKGHm7Bhz7sXMTzwfTgzcZ1gPsQ8Y8I9974jBcr5yEBvgsb8PjO5RWe2-x2UF5i8M7iK9ia7LJL-PI9nuNv45CdBZ9hcglpCwf5TR67_Uv0vDdDglfH8wL9_PzpdnE1u_7-5etifj2ztWjyTC4lWwq-tLJRsmk4NEZxUYNlvGG05ULVknTCit70daPa2nDDeNvIrpG07gS_QG8PvtsYHkZIWW9csjAMxkMYk2aSEqKEoqpI3xyl43IDnd5GtzFxr__EVAT0ILBlmhSh_yuhRE9V6LUuVeipCk2ZLlUURj1irMslpeBzNG54kvxwIKHEs3MQdbIOvIXOxZKk7oJ7kv74iLaDKyWZ4RfsIa3DGH3JXVOdCqBvpiWZdoQVP05kWwzafxv85_PfFPPJYg |
| CitedBy_id | crossref_primary_10_1097_IM9_0000000000000155 crossref_primary_10_1007_s12072_022_10382_z crossref_primary_10_1093_cid_ciae366 crossref_primary_10_1097_IM9_0000000000000152 crossref_primary_10_2147_IJWH_S511524 crossref_primary_10_1093_cid_ciae288 crossref_primary_10_1007_s11901_024_00659_2 crossref_primary_10_1016_j_ajog_2023_12_023 crossref_primary_10_1111_hepr_14048 crossref_primary_10_1097_ID9_0000000000000142 crossref_primary_10_1007_s10620_023_08258_9 crossref_primary_10_1016_j_jri_2024_104208 crossref_primary_10_1097_ID9_0000000000000122 crossref_primary_10_14309_ajg_0000000000003122 |
| Cites_doi | 10.1016/j.jhep.2017.03.021 10.1111/tbed.13674 10.1093/cid/ciaa1939 10.1542/peds.2015-2482 10.1016/j.clinre.2012.03.018 10.1111/apt.15064 10.1016/S0140-6736(15)60865-0 10.1053/j.gastro.2018.10.048 10.1016/S0140-6736(09)60695-4 10.1016/j.jinf.2017.05.012 10.1038/nrg2933 10.1056/NEJMoa1508660 10.1002/hep.29800 10.1016/S2468-1253(18)30056-6 10.1007/s12072-015-9675-4 10.1111/jvh.12834 10.1007/s12072-021-10235-1 10.1097/QAD.0000000000002880 10.1002/hep.27406 10.1016/S0140-6736(21)00314-7 10.1111/apt.16043 10.1093/cid/ciaa898 10.1016/S2468-1253(19)30042-1 |
| ContentType | Journal Article |
| Copyright | 2022 The Authors The Authors Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: 2022 The Authors – notice: The Authors – notice: Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved. |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.cgh.2021.12.012 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1542-7714 |
| EndPage | 2837.e9 |
| ExternalDocumentID | 34902570 10_1016_j_cgh_2021_12_012 S1542356521013069 1_s2_0_S1542356521013069 |
| Genre | Research Support, Non-U.S. Gov't Multicenter Study Journal Article |
| GeographicLocations | China |
| GeographicLocations_xml | – name: China |
| GrantInformation_xml | – fundername: The National Natural Science Foundation of China funderid: https://doi.org/10.13039/501100001809 |
| GroupedDBID | --- --K .1- .FO 0R~ 1B1 1CY 1P~ 29B 4.4 457 53G 5GY 5VS AAEDT AAEDW AAFWJ AALRI AAQFI AAQQT AAXUO ABJNI ABLJU ABMAC ACGFS ADBBV AENEX AEVXI AFJKZ AFRHN AFTJW AGCQF AITUG AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP BELOY C45 C5W CS3 DU5 EBS EFJIC EFKBS EJD F5P FDB FRP HZ~ IHE KOM M41 MO0 N9A NQ- O9- OBH OC. ON0 OVD P2P ROL RPZ SEL SES TEORI UV1 XH2 Z5R ADPAM AFCTW RIG 6I. AAFTH AAIAV AGZHU ALXNB ZA5 AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c458t-6b62b53bc6876883e8a7354ec238219357460d5c5faf48794a3a23986d8614d53 |
| ISSN | 1542-3565 1542-7714 |
| IngestDate | Fri Jul 11 01:36:42 EDT 2025 Thu Jan 02 22:55:05 EST 2025 Tue Jul 01 03:50:46 EDT 2025 Thu Apr 24 23:44:14 EDT 2025 Fri Feb 23 02:39:34 EST 2024 Tue Feb 25 20:04:42 EST 2025 Tue Aug 26 16:33:56 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Keywords | anti-HBs eGFR Chronic Hepatitis B Effectiveness HBeAg ALT HBsAg Mother-to-Child Transmission LMP Pregnancy Tenofovir Alafenamide TDF TAF Safety CHB MTCT Tenofovir Disoproxil Fumarate HBV WHO estimated glomerular filtration rate hepatitis B virus alanine aminotransferase hepatitis B e antigen World Health Organization hepatitis B surface antigen last menstrual period anti-hepatitis B surface antibody |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c458t-6b62b53bc6876883e8a7354ec238219357460d5c5faf48794a3a23986d8614d53 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-2094-4784 |
| OpenAccessLink | https://www.clinicalkey.com/#!/content/1-s2.0-S1542356521013069 |
| PMID | 34902570 |
| PQID | 2610075717 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2610075717 pubmed_primary_34902570 crossref_primary_10_1016_j_cgh_2021_12_012 crossref_citationtrail_10_1016_j_cgh_2021_12_012 elsevier_sciencedirect_doi_10_1016_j_cgh_2021_12_012 elsevier_clinicalkeyesjournals_1_s2_0_S1542356521013069 elsevier_clinicalkey_doi_10_1016_j_cgh_2021_12_012 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-12-01 |
| PublicationDateYYYYMMDD | 2022-12-01 |
| PublicationDate_xml | – month: 12 year: 2022 text: 2022-12-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Clinical gastroenterology and hepatology |
| PublicationTitleAlternate | Clin Gastroenterol Hepatol |
| PublicationYear | 2022 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | (bib11) 2018; 56 Zeng, Li, Ji (bib14) 2020; 67 Mossey, Little, Munger (bib19) 2009; 374 Chen, Gu, Bian (bib21) 2017; 75 Darrow, Greene, Mancini (bib36) 2015; 136 Thimm, Eke (bib9) 2021; 35 Lampertico, Agarwal, Berg (bib15) 2017; 67 Terrault, Lok, McMahon (bib16) 2018; 67 Lockman, Brummel, Ziemba (bib8) 2021; 397 Dixon, Marazita, Beaty (bib20) 2011; 12 (bib1) 2020 Li, Liu, Liu (bib18) 2021; 15 Wang, Fan, Zhang (bib2) 2014; 60 (bib5) 2019; 27 (bib10) 2010 Lopez, Cacoub, Macdougall (bib12) 2016; 387 Indolfi, Easterbrook, Dusheiko (bib4) 2019; 4 Polaris Observatory (bib3) 2018; 3 Ward, Hinman (bib6) 2019; 156 Ding, Cao, Zhu (bib17) 2020; 52 Zeng, Yu, Ji (bib7) 2021; 73 McKiernan (bib13) 2012; 36 Thimm (10.1016/j.cgh.2021.12.012_bib9) 2021; 35 Chen (10.1016/j.cgh.2021.12.012_bib21) 2017; 75 Ding (10.1016/j.cgh.2021.12.012_bib26) 2020; 52 Darrow (10.1016/j.cgh.2021.12.012_bib36) 2015; 136 Huang (10.1016/j.cgh.2021.12.012_bib30) 2021; 73 Wang (10.1016/j.cgh.2021.12.012_bib34) 2019; 49 Ward (10.1016/j.cgh.2021.12.012_bib6) 2019; 156 Polaris Observatory (10.1016/j.cgh.2021.12.012_bib3) 2018; 3 (10.1016/j.cgh.2021.12.012_bib31) 2010 Sarin (10.1016/j.cgh.2021.12.012_bib23) 2016; 10 (10.1016/j.cgh.2021.12.012_bib5) 2019; 27 Pan (10.1016/j.cgh.2021.12.012_bib33) 2016; 374 Mossey (10.1016/j.cgh.2021.12.012_bib19) 2009; 374 Zeng (10.1016/j.cgh.2021.12.012_bib7) 2021; 73 Lampertico (10.1016/j.cgh.2021.12.012_bib15) 2017; 67 Terrault (10.1016/j.cgh.2021.12.012_bib16) 2018; 67 Zeng (10.1016/j.cgh.2021.12.012_bib27) 2021; 73 McKiernan (10.1016/j.cgh.2021.12.012_bib13) 2012; 36 Hou (10.1016/j.cgh.2021.12.012_bib22) 2015; 23 Lockman (10.1016/j.cgh.2021.12.012_bib8) 2021; 397 Hu (10.1016/j.cgh.2021.12.012_bib29) 2018; 25 Li (10.1016/j.cgh.2021.12.012_bib18) 2021; 15 Lampertico (10.1016/j.cgh.2021.12.012_bib24) 2017; 67 (10.1016/j.cgh.2021.12.012_bib10) 2010 Yang (10.1016/j.cgh.2021.12.012_bib35) 2007; 23 Dixon (10.1016/j.cgh.2021.12.012_bib20) 2011; 12 Terrault (10.1016/j.cgh.2021.12.012_bib25) 2018; 67 (10.1016/j.cgh.2021.12.012_bib11) 2018; 56 (10.1016/j.cgh.2021.12.012_bib1) 2020 Ding (10.1016/j.cgh.2021.12.012_bib17) 2020; 52 Wang (10.1016/j.cgh.2021.12.012_bib2) 2014; 60 Zeng (10.1016/j.cgh.2021.12.012_bib14) 2020; 67 (10.1016/j.cgh.2021.12.012_bib32) 2018; 56 Lopez (10.1016/j.cgh.2021.12.012_bib12) 2016; 387 Indolfi (10.1016/j.cgh.2021.12.012_bib4) 2019; 4 (10.1016/j.cgh.2021.12.012_bib28) 2019; 27 |
| References_xml | – volume: 75 start-page: 146 year: 2017 end-page: 154 ident: bib21 article-title: Clinical course and perinatal transmission of chronic hepatitis B during pregnancy: a real-world prospective cohort study publication-title: J Infect – volume: 3 start-page: 383 year: 2018 end-page: 403 ident: bib3 article-title: Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study publication-title: Lancet Gastroenterol Hepatol – volume: 67 start-page: 370 year: 2017 end-page: 398 ident: bib15 article-title: EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection publication-title: J Hepatol – volume: 27 start-page: 938 year: 2019 end-page: 961 ident: bib5 article-title: The guidelines of prevention and treatment for chronic hepatitis B (2019 version) publication-title: Zhonghua Gan Zang Bing Za Zhi (Chinese Journal of Hepatology) – volume: 67 start-page: 1560 year: 2018 end-page: 1599 ident: bib16 article-title: Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance publication-title: Hepatology – volume: 136 start-page: 786 year: 2015 end-page: 791 ident: bib36 article-title: Diagnosis and management of infantile hemangioma: executive summary publication-title: Pediatrics – volume: 73 start-page: e3324 year: 2021 end-page: e3332 ident: bib7 article-title: Tenofovir alafenamide to prevent perinatal hepatitis B transmission: a multicenter, prospective, observational study publication-title: Clin Infect Dis – volume: 374 start-page: 1773 year: 2009 end-page: 1785 ident: bib19 article-title: Cleft lip and palate publication-title: Lancet – year: 2010 ident: bib10 article-title: Anthro for personal computers, version 3.2.2, 2011: software for assessing growth and development of the world’s children – volume: 56 start-page: 192 year: 2018 end-page: 199 ident: bib11 article-title: A national survey on physical growth and development of children under seven years of age in nine cities of China in 2015 publication-title: Zhonghua Er Ke Za Zhi (Chinese Journal of Pediatrics) – volume: 60 start-page: 2099 year: 2014 end-page: 2108 ident: bib2 article-title: The global burden of liver disease: the major impact of China publication-title: Hepatology – volume: 52 start-page: 1377 year: 2020 end-page: 1386 ident: bib17 article-title: Efficacy and safety of tenofovir alafenamide fumarate for preventing mother-to-child transmission of hepatitis B virus: a national cohort study publication-title: Aliment Pharmacol Ther – volume: 156 start-page: 297 year: 2019 end-page: 310 ident: bib6 article-title: What is needed to eliminate hepatitis B virus and hepatitis C virus as global health threats publication-title: Gastroenterology – volume: 4 start-page: 466 year: 2019 end-page: 476 ident: bib4 article-title: Hepatitis B virus infection in children and adolescents publication-title: Lancet Gastroenterol Hepatol – volume: 67 start-page: 2971 year: 2020 end-page: 2982 ident: bib14 article-title: Clinical course and treatment efficacy of COVID-19 near Hubei Province, China: a multicentre, retrospective study publication-title: Transbound Emerg Dis – volume: 36 start-page: 253 year: 2012 end-page: 256 ident: bib13 article-title: Neonatal jaundice publication-title: Clin Res Hepatol Gastroenterol – volume: 397 start-page: 1276 year: 2021 end-page: 1292 ident: bib8 article-title: Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial publication-title: Lancet – volume: 15 start-page: 1103 year: 2021 end-page: 1108 ident: bib18 article-title: Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load publication-title: Hepatol Int – volume: 387 start-page: 907 year: 2016 end-page: 916 ident: bib12 article-title: Iron deficiency anaemia publication-title: Lancet – volume: 35 start-page: 1319 year: 2021 end-page: 1320 ident: bib9 article-title: Tenofovir, pregnancy and renal function changes in pregnant women living with HIV publication-title: AIDS – year: 2020 ident: bib1 article-title: Prevention of mother-to-child transmission of hepatitis B virus: guidelines on antiviral prophylaxis in pregnancy – volume: 12 start-page: 167 year: 2011 end-page: 178 ident: bib20 article-title: Cleft lip and palate: understanding genetic and environmental influences publication-title: Nat Rev Genet – volume: 67 start-page: 370 year: 2017 ident: 10.1016/j.cgh.2021.12.012_bib15 article-title: EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection publication-title: J Hepatol doi: 10.1016/j.jhep.2017.03.021 – volume: 67 start-page: 2971 year: 2020 ident: 10.1016/j.cgh.2021.12.012_bib14 article-title: Clinical course and treatment efficacy of COVID-19 near Hubei Province, China: a multicentre, retrospective study publication-title: Transbound Emerg Dis doi: 10.1111/tbed.13674 – volume: 73 start-page: e3324 year: 2021 ident: 10.1016/j.cgh.2021.12.012_bib7 article-title: Tenofovir alafenamide to prevent perinatal hepatitis B transmission: a multicenter, prospective, observational study publication-title: Clin Infect Dis doi: 10.1093/cid/ciaa1939 – volume: 67 start-page: 370 year: 2017 ident: 10.1016/j.cgh.2021.12.012_bib24 article-title: EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection publication-title: J Hepatol doi: 10.1016/j.jhep.2017.03.021 – volume: 136 start-page: 786 year: 2015 ident: 10.1016/j.cgh.2021.12.012_bib36 article-title: Diagnosis and management of infantile hemangioma: executive summary publication-title: Pediatrics doi: 10.1542/peds.2015-2482 – volume: 27 start-page: 938 year: 2019 ident: 10.1016/j.cgh.2021.12.012_bib5 article-title: The guidelines of prevention and treatment for chronic hepatitis B (2019 version) publication-title: Zhonghua Gan Zang Bing Za Zhi (Chinese Journal of Hepatology) – volume: 36 start-page: 253 year: 2012 ident: 10.1016/j.cgh.2021.12.012_bib13 article-title: Neonatal jaundice publication-title: Clin Res Hepatol Gastroenterol doi: 10.1016/j.clinre.2012.03.018 – volume: 27 start-page: 938 year: 2019 ident: 10.1016/j.cgh.2021.12.012_bib28 article-title: The guidelines of prevention and treatment for chronic hepatitis B (2019 version) publication-title: Zhonghua Gan Zang Bing Za Zhi (Chinese Journal of Hepatology) – volume: 56 start-page: 192 year: 2018 ident: 10.1016/j.cgh.2021.12.012_bib32 article-title: A national survey on physical growth and development of children under seven years of age in nine cities of China in 2015 publication-title: Zhonghua Er Ke Za Zhi (Chinese Journal of Pediatrics) – year: 2020 ident: 10.1016/j.cgh.2021.12.012_bib1 – year: 2010 ident: 10.1016/j.cgh.2021.12.012_bib10 – volume: 49 start-page: 211 year: 2019 ident: 10.1016/j.cgh.2021.12.012_bib34 article-title: Real-world study of tenofovir disoproxil fumarate to prevent hepatitis B transmission in mothers with high viral load publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.15064 – year: 2010 ident: 10.1016/j.cgh.2021.12.012_bib31 – volume: 56 start-page: 192 year: 2018 ident: 10.1016/j.cgh.2021.12.012_bib11 article-title: A national survey on physical growth and development of children under seven years of age in nine cities of China in 2015 publication-title: Zhonghua Er Ke Za Zhi (Chinese Journal of Pediatrics) – volume: 387 start-page: 907 year: 2016 ident: 10.1016/j.cgh.2021.12.012_bib12 article-title: Iron deficiency anaemia publication-title: Lancet doi: 10.1016/S0140-6736(15)60865-0 – volume: 156 start-page: 297 year: 2019 ident: 10.1016/j.cgh.2021.12.012_bib6 article-title: What is needed to eliminate hepatitis B virus and hepatitis C virus as global health threats publication-title: Gastroenterology doi: 10.1053/j.gastro.2018.10.048 – volume: 374 start-page: 1773 year: 2009 ident: 10.1016/j.cgh.2021.12.012_bib19 article-title: Cleft lip and palate publication-title: Lancet doi: 10.1016/S0140-6736(09)60695-4 – volume: 75 start-page: 146 year: 2017 ident: 10.1016/j.cgh.2021.12.012_bib21 article-title: Clinical course and perinatal transmission of chronic hepatitis B during pregnancy: a real-world prospective cohort study publication-title: J Infect doi: 10.1016/j.jinf.2017.05.012 – volume: 12 start-page: 167 year: 2011 ident: 10.1016/j.cgh.2021.12.012_bib20 article-title: Cleft lip and palate: understanding genetic and environmental influences publication-title: Nat Rev Genet doi: 10.1038/nrg2933 – volume: 73 start-page: e3324 year: 2021 ident: 10.1016/j.cgh.2021.12.012_bib27 article-title: Tenofovir alafenamide to prevent perinatal hepatitis B transmission: a multicenter, prospective, observational study publication-title: Clin Infect Dis doi: 10.1093/cid/ciaa1939 – volume: 374 start-page: 2324 year: 2016 ident: 10.1016/j.cgh.2021.12.012_bib33 article-title: Tenofovir to prevent hepatitis B transmission in mothers with high viral load publication-title: N Engl J Med doi: 10.1056/NEJMoa1508660 – volume: 67 start-page: 1560 year: 2018 ident: 10.1016/j.cgh.2021.12.012_bib16 article-title: Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance publication-title: Hepatology doi: 10.1002/hep.29800 – volume: 3 start-page: 383 year: 2018 ident: 10.1016/j.cgh.2021.12.012_bib3 article-title: Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study publication-title: Lancet Gastroenterol Hepatol doi: 10.1016/S2468-1253(18)30056-6 – volume: 10 start-page: 1 year: 2016 ident: 10.1016/j.cgh.2021.12.012_bib23 article-title: Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update publication-title: Hepatol Int doi: 10.1007/s12072-015-9675-4 – volume: 25 start-page: 429 year: 2018 ident: 10.1016/j.cgh.2021.12.012_bib29 article-title: Safety and efficacy of telbivudine in late pregnancy to prevent mother-to-child transmission of hepatitis B virus: a multicenter prospective cohort study publication-title: J Viral Hepat doi: 10.1111/jvh.12834 – volume: 15 start-page: 1103 year: 2021 ident: 10.1016/j.cgh.2021.12.012_bib18 article-title: Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load publication-title: Hepatol Int doi: 10.1007/s12072-021-10235-1 – volume: 67 start-page: 1560 year: 2018 ident: 10.1016/j.cgh.2021.12.012_bib25 article-title: Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance publication-title: Hepatology doi: 10.1002/hep.29800 – volume: 23 start-page: 888 year: 2015 ident: 10.1016/j.cgh.2021.12.012_bib22 article-title: The guideline of prevention and treatment for chronic hepatitis B: a 2015 update publication-title: Zhonghua Gan Zang Bing Za Zhi (Chinese Journal of Hepatology) – volume: 35 start-page: 1319 year: 2021 ident: 10.1016/j.cgh.2021.12.012_bib9 article-title: Tenofovir, pregnancy and renal function changes in pregnant women living with HIV publication-title: AIDS doi: 10.1097/QAD.0000000000002880 – volume: 60 start-page: 2099 year: 2014 ident: 10.1016/j.cgh.2021.12.012_bib2 article-title: The global burden of liver disease: the major impact of China publication-title: Hepatology doi: 10.1002/hep.27406 – volume: 397 start-page: 1276 year: 2021 ident: 10.1016/j.cgh.2021.12.012_bib8 publication-title: Lancet doi: 10.1016/S0140-6736(21)00314-7 – volume: 52 start-page: 1377 year: 2020 ident: 10.1016/j.cgh.2021.12.012_bib17 article-title: Efficacy and safety of tenofovir alafenamide fumarate for preventing mother-to-child transmission of hepatitis B virus: a national cohort study publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.16043 – volume: 52 start-page: 1377 year: 2020 ident: 10.1016/j.cgh.2021.12.012_bib26 article-title: Efficacy and safety of tenofovir alafenamide fumarate for preventing mother-to-child transmission of hepatitis B virus: a national cohort study publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.16043 – volume: 73 start-page: e3317 year: 2021 ident: 10.1016/j.cgh.2021.12.012_bib30 article-title: Increased protection of earlier use of immunoprophylaxis in preventing perinatal transmission of hepatitis B virus publication-title: Clin Infect Dis doi: 10.1093/cid/ciaa898 – volume: 4 start-page: 466 year: 2019 ident: 10.1016/j.cgh.2021.12.012_bib4 article-title: Hepatitis B virus infection in children and adolescents publication-title: Lancet Gastroenterol Hepatol doi: 10.1016/S2468-1253(19)30042-1 – volume: 23 start-page: 474 year: 2007 ident: 10.1016/j.cgh.2021.12.012_bib35 article-title: Discussion on the sample size of clinical trial for drug safety evaluation (in Chinese) publication-title: Chin J Clin PharmacoI |
| SSID | ssj0029497 |
| Score | 2.5316377 |
| Snippet | Data on long-term tenofovir alafenamide (TAF) therapy for pregnant women with active chronic hepatitis B (CHB) (immune clearance and reactivation phases,... Background & AimsData on long-term tenofovir alafenamide (TAF) therapy for pregnant women with active chronic hepatitis B (CHB) (immune clearance and... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2826 |
| SubjectTerms | Adenine - adverse effects Adult Antiviral Agents - adverse effects China Chronic Hepatitis B Cleft Lip - chemically induced Cleft Lip - drug therapy Cleft Palate - chemically induced Cleft Palate - drug therapy Effectiveness Female Gastroenterology and Hepatology Hepatitis B - diagnosis Hepatitis B Surface Antigens Hepatitis B, Chronic - drug therapy Humans Infant, Newborn Mother-to-Child Transmission Pregnancy Pregnant Women Prospective Studies Safety Tenofovir - adverse effects Tenofovir Alafenamide Tenofovir Disoproxil Fumarate |
| Title | Tenofovir Alafenamide for Pregnant Chinese Women With Active Chronic Hepatitis B: A Multicenter Prospective Study |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1542356521013069 https://www.clinicalkey.es/playcontent/1-s2.0-S1542356521013069 https://dx.doi.org/10.1016/j.cgh.2021.12.012 https://www.ncbi.nlm.nih.gov/pubmed/34902570 https://www.proquest.com/docview/2610075717 |
| Volume | 20 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZKJyFeEHfKTUbiiSpV6ti58NZNoGpjiMsmCi9WLk7XaSTQJDzwV_iznJPYabp2A_YSVYntOD2ffc6xv3NMyIvUiyPmp4nlu15qcRGFVqB4YiUJZ5FAUNUb7Yfv3Okx35-JWa_3u8NaqspoFP_aGldyFanCPZArRsn-h2TbRuEG_Ab5whUkDNd_k7HK8jT_uVgOJ2dhqvBs-aRJ4v1-qeZIcanPx1YFkma-KaTI4CZNPcUNdVpcUDxIqi4XxXC3CVOvY3KRtKmwndzEYtaUw7VN4D0TVTkPi3KZ1zVWKZ1OsN21RfuvqplYPoC6tN6qxcai9TSHB7Nq4_7-wvpSrWA8rcwi90mVd5ctGDtHAWnjadbonmDPYWxBc3qEmZ-Z3cUh6862PnM7mhsT-YxUsFUxNGsUp6N4jjtQbFyvAevG1vNtf8JOYB_AGQYF7wbXyA4DH4T1yc7k4OPng9afD3hzdo_ptNk0r-mD5150kdlzkVtTmzdHt8hN7ZfQSQOy26Snsjvk-qFmXtwlP1qs0Q7WKGCNGqxRjTVaY40i1miDNaqxRlus0d1XdEI7SKMdpNEaaffI8ZvXR3tTSx_XYcVc-KXlRi4O7yh2QcP6vqP80HMEVzFYhaAXHeFx105ELNIwBTc54KETYvZJN_HBRkyEc5_0szxTDwn1wchWjq2E8mweiRALqHgcJeBfp7YXDIht_k0Z61z2eKTKmTSkxVMJApAoADlmEgQwIC_bKt-bRC6XFWZGRNJEKINOlYCmyyp52yqpQs8YhRzLAkrKDYQNCG9rasO3MWj_9sLnBj0SlALu9IWZyqtCMhfJT8IbewPyoIFV-9EOR2aBZz-6yjc-JjdWg_kJ6ZfLSj0Fq7yMnunR8QdzheDK |
| linkProvider | Library Specific Holdings |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Tenofovir+Alafenamide+for+Pregnant+Chinese+Women+With+Active+Chronic+Hepatitis+B%3A+A+Multicenter+Prospective+Study&rft.jtitle=Clinical+gastroenterology+and+hepatology&rft.au=Zeng%2C+Qing-Lei&rft.au=Zhang%2C+Hong-Xu&rft.au=Zhang%2C+Ji-Yuan&rft.au=Huang%2C+Shuo&rft.date=2022-12-01&rft.pub=Elsevier+Inc&rft.issn=1542-3565&rft.volume=20&rft.issue=12&rft.spage=2826&rft.epage=2837.e9&rft_id=info:doi/10.1016%2Fj.cgh.2021.12.012&rft.externalDocID=S1542356521013069 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F15423565%2FS1542356522X00116%2Fcov150h.gif |